Two New Patents Granted to HeartBeam for Cardiac Diagnostics Tech

HeartBeam has secured two new U.S. patents that significantly enhance its intellectual property portfolio and strengthen its position in cardiac monitoring technology.

The first patent protects the company’s credit card–sized, cable-free 3D ECG device designed to capture high-fidelity electrical signals from chest and finger electrodes in three noncoplanar directions. This portable device enables users to record their cardiac symptoms in real-time and synthesizes the recordings into a familiar 12-lead ECG reading through a personalized transformational matrix. The 12-led ECG synthesis software currently is under U.S. Food and Drug Administration (FDA) review, supported by data from the VALID-ECG pivotal study.

The second patent covers the company’s rhythm analysis algorithm, which classifies heart rhythms such as sinus rhythm, atrial fibrillation and other arrhythmias, by continuously analyzing signal input. Designed for integration with any cardiac monitoring system, including wearables, it provides on-device, risk-based escalation by detecting anomalies and prompting users to record high-fidelity 3D ECG signals for 12-lead synthesis. HeartBeam plans to submit the rhythm analysis algorithm for FDA clearance in the future.

“HeartBeam’s vision is to make it easier for patients and physicians to monitor and diagnose cardiac symptoms outside of a medical facility,” HeartBeam CEO Robert Eno said. “The new patents add to our growing IP portfolio, enabling us to expand the reach and impact of our groundbreaking 3D ECG technology as we strive to transform the future of cardiac care.”

These patents significantly bolster the defensive moat around HeartBeam’s core technology, enabling future product extensions in areas such as AI-driven arrhythmia classification and ischemia detection, according to the company. Their addition brings the company’s IP holdings to more than 20 issued U.S. and international patents, two allowed patents and 32 pending applications.

BEAT’s platform centers on its proprietary 3D ECG technology, which collects the heart’s electrical signals in three distinct noncoplanar directions and transforms those signals into synthesized 12-lead ECGs. This platform technology is designed for use in a range of form factors, including credit card–sized monitors, extended-wear patches and wrist-worn devices. This approach empowers physicians to monitor patients remotely and direct them to appropriate care outside traditional medical facilities.

HeartBeam’s broadened patent portfolio may strengthen investor confidence by positioning the company securely in a highly competitive medical device landscape. Am IP framework is a critical asset in the system of portable devices aimed at transforming cardiac care delivery. As HeartBeam moves toward broader clinical adoption and regulatory milestones, the two newly issued patents offer added protection and commercialization leverage. They lay the groundwork for future enhancements while strengthening partnerships and facilitating market access.

HeartBeam has created the first cable-free device capable of collecting ECG signals in 3D. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care—all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software is under FDA review.